{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:28:01Z","timestamp":1776788881472,"version":"3.51.2"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,13]]},"DOI":"10.7759\/cureus.30269","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T16:42:10Z","timestamp":1665679330000},"source":"Crossref","is-referenced-by-count":8,"title":["Complete, Rapid Resolution of Severe Bilateral Pneumonia and Acute Respiratory Distress Syndrome in a COVID-19 Patient: Role for a Unique Therapeutic Combination of Inhalations With Bromhexine, Higher Doses of Colchicine, and Hymecromone"],"prefix":"10.7759","author":[{"given":"Tsanko","family":"Mondeshki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radoslav","family":"Bilyukov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toma","family":"Tomov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslav","family":"Mihaylov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanyo","family":"Mitev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000786","article-title":"TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells","volume":"3","author":"Bestle D","year":"2020","unstructured":"Bestle D, Heindl MR, Limburg H, et al.. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance. 2020, 3:10.26508\/lsa.202000786","journal-title":"Life Sci Alliance"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.19.20071647","article-title":"Accelerated hyaluronan concentration as the primary driver of morbidity and mortality in high-risk COVID-19 patients: with therapeutic introduction of an oral hyaluronan inhibitor in the prevention of induced hyaluronan storm syndrome [Preprint]","author":"Mong MA","year":"2020","unstructured":"Mong MA, Awkal JA, Marik PE. Accelerated hyaluronan concentration as the primary driver of morbidity and mortality in high-risk COVID-19 patients: with therapeutic introduction of an oral hyaluronan inhibitor in the prevention of induced hyaluronan storm syndrome [Preprint]. medRxiv. 2020, 10.1101\/2020.04.19.20071647","journal-title":"medRxiv"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219174","article-title":"Anti-inflammatory therapy for COVID-19 infection: the case for colchicine","volume":"80","author":"Reyes AZ","year":"2021","unstructured":"Reyes AZ, Hu KA, Teperman J, Wampler Muskardin TL, Tardif JC, Shah B, Pillinger MH. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Ann Rheum Dis. 2021, 80:550-7. 10.1136\/annrheumdis-2020-219174","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu Z","year":"2020","unstructured":"Xu Z, Shi L, Wang Y, et al.. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020, 8:420-2. 10.1016\/S2213-2600(20)30076-X","journal-title":"Lancet Respir Med"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104853","article-title":"Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2","volume":"157","author":"Habtemariam S","year":"2020","unstructured":"Habtemariam S, Nabavi SF, Ghavami S, Cismaru CA, Berindan-Neagoe I, Nabavi SM. Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2. Pharmacol Res. 2020, 157:104853.","journal-title":"Pharmacol Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.34172\/ipp.2021.12","article-title":"Controversy with bromhexine in COVID-19; where we stand","volume":"7","author":"Tolouian R","year":"2021","unstructured":"Tolouian R, Mulla Z. Controversy with bromhexine in COVID-19; where we stand. Immunopathologia Persa. 2021, 7:12. 10.34172\/ipp.2021.12","journal-title":"Immunopathologia Persa"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00435-5","article-title":"Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"9","author":"Horby PW","year":"2021","unstructured":"Horby PW, Campbell M, Spata E, et al.. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respir Med. 2021, 9:1419-26. 10.1016\/S2213-2600(21)00435-5","journal-title":"Lancet Respir Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.26.21250494","article-title":"Efficacy of colchicine in non-hospitalized patients with COVID-19 [Preprint]","author":"Tardif JC","year":"2021","unstructured":"Tardif JC, Bouabdallaoui N, L'Allier PL, et al.. Efficacy of colchicine in non-hospitalized patients with COVID-19 [Preprint]. medRxiv. 2021, 10.1101\/2021.01.26.21250494","journal-title":"medRxiv"},{"key":"ref9","article-title":"\u0422reatment with inhaled bromhexine, high doses of colchicine and hymecromon\u0435 reduced hospital mortality between 4 and 5 times [Article in Bulgarian]","volume":"3-4","author":"Mondeshki T","year":"2022","unstructured":"Mondeshki T, Ivanov K, Mitev V. \u0422reatment with inhaled bromhexine, high doses of colchicine and hymecromon\u0435 reduced hospital mortality between 4 and 5 times [Article in Bulgarian]. Medizina i Sport. 2022, 3-4:42-7.","journal-title":"Medizina i Sport"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub RA","year":"2010","unstructured":"Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010, 62:1060-8. 10.1002\/art.27327","journal-title":"Arthritis Rheum"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-020-0530-3","article-title":"COVID-19 infection: the perspectives on immune responses","volume":"27","author":"Shi Y","year":"2020","unstructured":"Shi Y, Wang Y, Shao C, et al.. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020, 27:1451-4. 10.1038\/s41418-020-0530-3","journal-title":"Cell Death Differ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2018.06.006","article-title":"Defective lung function following influenza virus is due to prolonged, reversible hyaluronan synthesis","volume":"80","author":"Bell TJ","year":"2019","unstructured":"Bell TJ, Brand OJ, Morgan DJ, et al.. Defective lung function following influenza virus is due to prolonged, reversible hyaluronan synthesis. Matrix Biol. 2019, 80:14-28. 10.1016\/j.matbio.2018.06.006","journal-title":"Matrix Biol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3185","article-title":"Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells","volume":"70","author":"Lokeshwar VB","year":"2010","unstructured":"Lokeshwar VB, Lopez LE, Munoz D, et al.. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res. 2010, 70:2613-23. 10.1158\/0008-5472.CAN-09-3185","journal-title":"Cancer Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.17179\/excli2020-3215","article-title":"Unraveled roles of hyaluronan in severe COVID-19","volume":"20","author":"Ontong P","year":"2021","unstructured":"Ontong P, Prachayasittikul V. Unraveled roles of hyaluronan in severe COVID-19. EXCLI J. 2021, 20:117-25. 10.17179\/excli2020-3215","journal-title":"EXCLI J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.AC120.015967","article-title":"Presence of hyaluronan in lung alveoli in severe Covid-19: an opening for new treatment options?","volume":"295","author":"Hellman U","year":"2020","unstructured":"Hellman U, Karlsson MG, Engstr\u00f6m-Laurent A, et al.. Presence of hyaluronan in lung alveoli in severe Covid-19: an opening for new treatment options?. J Biol Chem. 2020, 295:15418-22. 10.1074\/jbc.AC120.015967","journal-title":"J Biol Chem"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.04.361576","article-title":"Human identical sequences of SARS-CoV-2 promote clinical progression of COVID-19 by upregulating hyaluronan via NamiRNA-Enhancer Network [Preprint]","author":"Li W","year":"2020","unstructured":"Li W, Yang S, Xu P, et al.. Human identical sequences of SARS-CoV-2 promote clinical progression of COVID-19 by upregulating hyaluronan via NamiRNA-Enhancer Network [Preprint]. bioRxiv. 2020, 10.1101\/2020.11.04.361576","journal-title":"bioRxiv"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00123","article-title":"4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer","volume":"6","author":"Nagy N","year":"2015","unstructured":"Nagy N, Kuipers HF, Frymoyer AR, Ishak HD, Bollyky JB, Wight TN, Bollyky PL. 4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. Front Immunol. 2015, 6:123. 10.3389\/fimmu.2015.00123","journal-title":"Front Immunol"},{"key":"ref18","article-title":"Outpatient treatment of Covid-19 [Article in Bulgarian]","volume":"1-2","author":"Mitev V","year":"2021","unstructured":"Mitev V. Outpatient treatment of Covid-19 [Article in Bulgarian]. Medizina i Sport. 2021, 1-2:4-10.","journal-title":"Medizina i Sport"},{"key":"ref19","article-title":"Treatment of COVID-19 with colchicine and inhaled bromhexine [Article in Bulgarian]","volume":"1-2","author":"Mitev V","year":"2022","unstructured":"Mitev V, Mondeshki T. Treatment of COVID-19 with colchicine and inhaled bromhexine [Article in Bulgarian]. Medizina i Sport. 2022, 1-2:3-7.","journal-title":"Medizina i Sport"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/119576-complete-rapid-resolution-of-severe-bilateral-pneumonia-and-acute-respiratory-distress-syndrome-in-a-covid-19-patient-role-for-a-unique-therapeutic-combination-of-inhalations-with-bromhexine-higher-doses-of-colchicine-and-hymecromone","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:41:50Z","timestamp":1707507710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/119576-complete-rapid-resolution-of-severe-bilateral-pneumonia-and-acute-respiratory-distress-syndrome-in-a-covid-19-patient-role-for-a-unique-therapeutic-combination-of-inhalations-with-bromhexine-higher-doses-of-colchicine-and-hymecromone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.30269","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,13]]}}}